Volume 9, Number 7—July 2003
Research
Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae: Redefining Fluoroquinolone Resistance
Sue Lim*†, Darrin Bast*†, Allison McGeer*†, Joyce de Azavedo*†, and Donald E. Low*†
Table 4
Characterization of Streptococcus pneumoniae isolates with levofloxacin MIC 4 μg/mLa
| Isolate no. | Amino acid substitution |
Change in MIC with inhibition of efflux | |
|---|---|---|---|
| In ParC | In GyrA | ||
| 1 | Ser79→Phe | None | 8-fold |
| 2 | Ser79→Phe | None | No effect |
| 3 | Asp78→Asn | Ser81→Phe | No effect |
| 4 | Ala115→Pro | Ser81→Phe | No effect |
| 5 | Ser79→Phe | None | No effect |
| 6 | Ser79→Phe | None | No effect |
| 7 | None | None | 4-fold |
| 8 | Ser79→Phe | Ser81→Phe | No effect |
aparE and gyrB sequencing was performed on all isolates, but no mutations were found in the quinolone-resistance–determining region.
Page created: December 22, 2010
Page updated: December 22, 2010
Page reviewed: December 22, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.